Medical Imaging Convention [rescheduled] Mar 09, 2021 - Mar 10, 2021 — National Exhibition Centre, Birmingham, England
9th SINAPSE Neuro-oncology Imaging Meeting [rescheduled] Mar 11, 2021 09:30 AM - 03:30 PM — West Park Conferencing & Events, 319 Perth Road, Dundee DD2 1NN
Total Body PET 2020 conference [rescheduled] Jun 05, 2021 - Jun 07, 2021 — McEwan Hall, University of Edinburgh


SINAPSE experts from around Scotland have developed ten online modules designed to explain medical imaging. They are freely available and are intended for non-specialists.

Edinburgh Imaging Academy at the University of Edinburgh offers the following online programmes through a virtual learning environment:

Neuroimaging for Research MSc/Dip/Cert

Imaging MSc/Dip/Cert

PET-MR Principles & Applications Cert

Applied Medical Image Analysis Cert

Online Short Courses

Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model

Author(s): R. J. Mairs, C. L. Wideman, W. J. Angerson, T. L. Whateley, M. S. Reza, J. R. Reeves, L. M. Robertson, A. Neshasteh-Riz, R. Rampling, J. Owens, D. Allan, D. I. Graham

The Auger electron emitting agent 5-[I-125]iodo-2'-deoxyuridine (i.e. [I-125]IUdR) holds promise for the treatment of residual glioma after surgery because this thymidine analogue kills only proliferating cells. However, malignant cells which are not synthesizing DNA during exposure to the radiopharmaceutical will be spared. To determine whether tumour incorporation of [I-125]IUdR could be enhanced by protracted administration, we used a C6 cell line, growing in the brains of Wistar rats, as a glioma model and compared three methods of intracerebral delivery of [I-125]IUdR. Twenty-four hours after administration of drug, autoradiography of brain sections demonstrated nuclear uptake of the radiopharmaceutical in cells throughout tumour while normal brain cells remained free of radioactivity, The [I-125]IUdR labelling indices (Sb +/- s.e.m.) achieved were 6.2 (0.4) by single injection, 22.5 (4.1) using a sustained release polymer implant (poly(lactide-co-glycolide)) and 34.3 (2.0) by mini-osmotic pump, These results emphasize the need for a sustained delivery system as a prerequisite for effective treatment. These findings are also encouraging for the development of a sustained release system for radiolabelled IUdR for use in the treatment of intracranial tumours, particularly in the immediate postoperative setting. (C) 2000 Cancer Research campaign.

Full version: Available here

Click the link to go to an external website with the full version of the paper

ISBN: 0007-0920
Publication Year: 2000
Periodical: British Journal of Cancer
Periodical Number: 1
Volume: 82
Pages: 74-80
Author Address: